Changing it Up | GenomeWeb

Changing it Up

Drug discovery is harder than it used to be, says Technology Review's Susan Young. Pharma pipelines are freezing up and fewer drugs are getting past early-stage testing. Further, there are entrepreneurs who have new ideas, but no money to bring them to completion, Young says. So pharma, biotech, and academia are trying to solve their collective problems by coming together with venture capitalists to create new drug discovery funding models, she adds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.